Overview

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Crizotinib